[메디게이트뉴스 서민지 기자] Daewoong Pharmaceutical announced on the 9th that it will voluntarily suspend Phase 3 clinical trials of DWJ1248, a corona treatment, for patients with severe COVID-19 (COVID-19).
The clinical trial to be suspended this time is a double-blind, randomized, placebo-controlled, multi-center clinical trial to evaluate the efficacy and safety of combination therapy of DWJ1248 (ingredient name camostat mesylate) and remdesivir in patients with severe COVID-19 . to be.
It has been running for about two years after receiving approval for a clinical trial plan (IND) from the Ministry of Food and Pharmaceutical Safety on December 31, 2020, but it was decided to stop it for reasons such as business viability.
Daewoong Pharmaceutical said, “It is anticipated that there will be difficulties in achieving clinical outcomes as the transition rate to critically ill patients decreases due to the rapidly evolving Corona 19 situation and the expansion of vaccination.” it was formulated on the basis of the opinions of competent experts and the judgment on the economic feasibility of the investment”.
Previously, at the end of last year, Daewoong Pharmaceutical halted its Phase 3 domestic clinical trial of DWJ1248 (ingredient name camostat mesylate) for COVID-19 prevention due to difficulties in recruiting and enrolling clinical trial subjects. Clinical trials for the treatment of even moderately ill patients have been withdrawn. With clinical trials suspended for critically ill patients, Daewoong Pharmaceutical has concluded all clinical trials for COVID-19 treatments.
